technology
Radioligand therapy
Also known as radiopharmaceutical therapy, radionuclide therapy, RLT, theranostics
Radioligand therapy pairs a targeting molecule with a radioactive isotope so radiation is delivered to cancer cells anywhere in the body, rather than aimed from outside.[1] Two agents anchor the field: 177Lu-Dotatate, approved in 2018 for neuroendocrine tumours, and Pluvicto for PSMA-positive prostate cancer, approved in 2022 and extended to earlier disease in July 2026.[2][3][4]
Key facts
Radioligand therapy inverts the usual geometry of radiation treatment. Instead of aiming beams at a tumour from outside, the drug is built from a radioactive molecule, a targeting molecule that latches onto cancer cells and a linker joining the two, then infused so it finds target cells wherever they are.[1]
This page is general information, not medical advice. Eligibility for these therapies depends on imaging and prior treatment, and those decisions belong with an oncology team.
How it works
Once a radioligand binds its target, NCI says the energy released can reach the bound cell and, depending on the isotope, about 10 to 30 surrounding cells, which increases the number of cancer cells a single molecule can kill.[5] For a different way of delivering a payload to cancer cells, see antibody-drug conjugates.
Many newer radiopharmaceuticals are re-engineered versions of compounds already used in nuclear imaging. When the imaging and treatment molecules share a target, a scan can give doctors a preview of whether the treatment is likely to work.[6]
The neuroendocrine tumour result
NCI describes the field’s turning point as the FDA’s 2018 approval of lutetium Lu 177-dotatate (Lutathera) for certain cancerous neuroendocrine tumours of the digestive tract, which showed that solid tumours could be targeted with a radiopharmaceutical built from scratch.[2] The phase 3 NETTER-1 trial behind it randomised 229 patients with advanced midgut neuroendocrine tumours: estimated progression-free survival at month 20 was 65.2% with 177Lu-Dotatate against 10.8% with high-dose octreotide, and 18% of patients responded against 3%.[7]
The prostate cancer result
The larger test came in prostate cancer. In the phase 3 VISION trial, 831 of 1,179 screened men with PSMA-positive metastatic castration-resistant disease were randomised; adding 177Lu-PSMA-617 to standard care extended median imaging-based progression-free survival to 8.7 months from 3.4, and median overall survival to 15.3 months from 11.3, a hazard ratio for death of 0.62.[8] Grade 3 or higher adverse events were more common with treatment, at 52.7% against 38.0%, while the trial reported no adverse effect on quality of life.[9]
On 23 March 2022 the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) on that basis, described by Novartis as the first targeted radioligand therapy for the disease; the most common adverse events in the treatment arm were fatigue (43%), dry mouth (39%), nausea (35%) and anaemia (32%).[3]
Moving earlier in treatment
A 2026 review in European Urology Focus reports that three phase 3 trials with published, presented or announced results, PSMAfore, SPLASH and ECLIPSE, showed PSMA radioligand therapy delaying progression compared with switching to another androgen receptor pathway inhibitor, in chemotherapy-naive patients whose disease had progressed on one.[10] On 31 July 2026 Novartis said the FDA had approved Pluvicto with such a drug for PSMA-positive metastatic hormone-sensitive prostate cancer, based on the phase 3 PSMAddition trial, where the combination cut the risk of progression or death by 28% against standard care alone (33% at an updated analysis).[4] The company said the overall survival data were still maturing, and these figures are its own account of its trial.[4]
What limits it
NCI identifies the shortage of clinicians trained to administer these drugs as a practical constraint, and notes that although research to date has not shown a high rate of late effects, long-term safety studies are still needed.[11] The randomised results above are measured in months: delayed progression in NETTER-1 and VISION, and in VISION a median survival gain of about four months.[7][8]
For the underlying physics, read radioactivity and half-life; for the disease, the prostate cancer explainer.
Read next
Antibody-drug conjugates (ADCs)
Antibody-drug conjugates link an antibody to a toxic payload. Not immunotherapy themselves, they are increasingly paired with checkpoint inhibitors.
Questions readers ask
What is radioligand therapy?
A cancer drug built from three parts: a radioactive molecule, a targeting molecule that binds cancer cells, and a linker joining them, so radiation reaches target cells anywhere in the body.[1]
How far does the radiation travel?
NCI says that depending on the isotope the energy released can reach the bound cell and about 10 to 30 surrounding cells.[5]
Which cancers is it approved for?
Certain neuroendocrine tumours of the digestive tract, from 2018, and PSMA-positive metastatic prostate cancer, from 2022, extended in July 2026 to hormone-sensitive metastatic disease.[2][3][4]
How large is the benefit?
In the phase 3 VISION trial, adding 177Lu-PSMA-617 to standard care extended median overall survival to 15.3 months from 11.3, and imaging-based progression-free survival to 8.7 months from 3.4.[8]
What are the side effects?
In VISION, grade 3 or higher adverse events occurred in 52.7% of treated patients versus 38.0% without. The most common events in the Pluvicto approval trial arm were fatigue, dry mouth, nausea and anaemia.[9][3]
What limits its use?
NCI points to the shortage of clinicians trained to administer these drugs, and says long-term safety studies are still needed even though research to date has not shown a high rate of late effects.[11]
Sources
· 11 claims from 4 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
A radioligand (radiopharmaceutical) therapy is built from three parts: a radioactive molecule, a targeting molecule that latches onto cancer cells, and a linker joining them, so that radiation is delivered to cells wherever they are in the body. confirmedas of 2026-11-14
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer · Novartis · Primary source · 2026-07-31 (retrieved 2026-11-14)
- [2]
NCI describes the field's turning point as the FDA's 2018 approval of lutetium Lu 177-dotatate (Lutathera) for certain neuroendocrine tumours of the digestive tract, which showed that solid tumours could be targeted with a radiopharmaceutical built from scratch. confirmedas of 2020-10-26
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- [3]
On 23 March 2022 the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer, which Novartis described as the first targeted radioligand therapy for that disease; the most common adverse events in the trial arm were fatigue (43%), dry mouth (39%), nausea (35%) and anaemia (32%). confirmedas of 2022-03-23
- Novartis Pluvicto approved by FDA as first targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer · Novartis · Primary source · 2022-03-23 · Headline (retrieved 2026-11-14)
- Novartis Pluvicto approved by FDA as first targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer · Novartis · Primary source · 2022-03-23 (retrieved 2026-11-14)
- Novartis Pluvicto approved by FDA as first targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer · Novartis · Primary source · 2022-03-23 (retrieved 2026-11-14)
- [4]
On 31 July 2026 Novartis said the FDA had approved Pluvicto with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, based on the phase 3 PSMAddition trial, in which the combination cut the risk of progression or death by 28% (hazard ratio 0.72) against standard care, and by 33% (hazard ratio 0.67) at an updated analysis; overall survival data were still maturing, with a hazard ratio of 0.80 whose confidence interval crossed 1 (company-reported). confirmedas of 2026-07-31
- FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer · Novartis · Primary source · 2026-07-31 (retrieved 2026-11-14)
- FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer · Novartis · Primary source · 2026-07-31 (retrieved 2026-11-14)
- FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer · Novartis · Primary source · 2026-07-31 (retrieved 2026-11-14)
- [5]
NCI says that, depending on the radioactive compound, the energy released can reach the cell a radiopharmaceutical is bound to and about 10 to 30 surrounding cells, increasing the number of cancer cells a single molecule can kill. confirmedas of 2020-10-26
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- [6]
Many newer radiopharmaceuticals are re-engineered versions of compounds used in nuclear imaging, and when the imaging and treatment molecules share a target, a scan can preview whether the treatment is likely to work; NCI gives the example of a trial requiring a PSMA PET scan first. confirmedas of 2020-10-26
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- [7]
The phase 3 NETTER-1 trial randomised 229 patients with advanced midgut neuroendocrine tumours; estimated progression-free survival at month 20 was 65.2% with 177Lu-Dotatate versus 10.8% with high-dose octreotide, and the response rate was 18% versus 3%. confirmedas of 2017-01-01
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NEJM, 2017; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2017-01-01 · Methods (retrieved 2026-11-14)
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NEJM, 2017; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2017-01-01 · Results (retrieved 2026-11-14)
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NEJM, 2017; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2017-01-01 · Results (retrieved 2026-11-14)
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NEJM, 2017; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2017-01-01 · Results (retrieved 2026-11-14)
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NEJM, 2017; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2017-01-01 · Results (retrieved 2026-11-14)
- [8]
In the phase 3 VISION trial, 831 of 1,179 screened men with PSMA-positive metastatic castration-resistant prostate cancer were randomised; adding 177Lu-PSMA-617 to standard care extended median imaging-based progression-free survival to 8.7 months from 3.4 and median overall survival to 15.3 months from 11.3 (hazard ratio for death 0.62). confirmedas of 2021-06-23
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- [9]
In VISION, grade 3 or higher adverse events were more common with 177Lu-PSMA-617 than without, at 52.7% versus 38.0%, while the trial reported that quality of life was not adversely affected. confirmedas of 2021-06-23
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (NEJM, 2021; Europe PMC record) · New England Journal of Medicine (via Europe PMC) · Primary source · 2021-06-23 · Results (retrieved 2026-11-14)
- [10]
A 2026 review in European Urology Focus says three phase 3 trials with published, presented or announced results, PSMAfore, SPLASH and ECLIPSE, showed PSMA radioligand therapy delaying progression compared with switching androgen receptor pathway inhibitor in chemotherapy-naive patients whose disease had progressed on one such drug. confirmedas of 2026-06-24
- How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management? (European Urology Focus, 2026; Europe PMC record) · European Urology Focus (via Europe PMC) · Primary source · 2026-06-24 · Abstract (retrieved 2026-11-14)
- [11]
NCI identifies a shortage of clinicians trained to give these drugs as a constraint on wider use, and says that although research to date has not shown a high rate of late effects, long-term safety studies are still needed. confirmedas of 2020-10-26
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
- Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age · National Cancer Institute · Primary source · 2020-10-26 (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 14, 2026. Next scheduled review: Mar 8, 2027.
Cite this page
"Radioligand therapy." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/radioligand-therapy
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.